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Objectives: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). The
implications of treatment with tofacitinib on cardiovascular (CV) risk in RA are unknown. Therefore, CV
adverse events (AEs), and blood pressure and lipid level changes, in tofacitinib-treated patients with RA
were evaluated.
Methods: Data were pooled from six Phase (P)3 studies (24 months) and two open-label long-term
extension (LTE) studies (60 months) of tofacitinib in patients with RA and inadequate response to
DMARDs. Tofacitinib was administered alone or with non-biologic DMARDs. CV events, including major
adverse CV events (MACE: CV death and non-fatal CV events) and congestive heart failure (CHF), were
assessed by a blinded adjudication committee.
Results: Overall, 4271 patients from P3 studies and 4827 enrolled from P2/P3 studies into LTE studies
were evaluated, representing 3942 and 8699 patient-years of exposure to tofacitinib, respectively. Blood
pressure remained stable over time across studies. The number of investigator-reported hypertension-
related AEs in tofacitinib-treated patients was low in P3 studies (Months 0–3: 2.8%; Months 3–6: 1.4%;
46 months: 2.8%). Across studies, lipid level increases were generally observed within 1–3 months of
treatment and stabilized thereafter. Patients with events (incidence rate [IR]/100 patient-years) for MACE
and CHF, respectively, were: 23 (0.58) and 9 (0.23) in P3 studies, and 32 (0.37) and 8 (0.09) in LTE studies;
IRs were comparable with placebo (P3) and did not increase over time (LTE).
Conclusions: Tofacitinib was associated with a low incidence of CV events in a large Phase 3 program,
including LTE studies. Further long-term studies are underway.
& 2016 The Authors. Published by Elsevier HS Journals, Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).r HS Journals, Inc. This is an open access article under the CC BY-NC-ND license
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Patients with rheumatoid arthritis (RA) have an increased risk
of cardiovascular (CV) disease and CV-related death compared
with the general population [1–3]. CV events are reported to occur
approximately a decade earlier in patients with RA compared with
the general population [4,5], suggesting that RA is an independent
risk factor for premature heart disease [2,6]. CV disease risk in
older patients (Z75 years) with RA was reported to be more than
three-fold the Framingham-predicted risk for the general popula-
tion [7], and female patients with RA have demonstrated a two-
fold higher risk of myocardial infarction (MI) compared with
female patients without RA [8].
The increased risk of CV disease in patients with RA appears to
be linked to coronary atherosclerosis [9,10]. Studies have also
suggested that the increased risk is not driven by traditional CV
risk factors alone [6,11–13], and RA-associated inﬂammation and
disease activity play a pivotal role [14,15]. The relationship
between lipid levels, RA treatment, and CV risk in patients with
RA is complex. Indeed, although the evidence is inconclusive, some
data indicate that effective management of RA with disease-
modifying anti-rheumatic drugs (DMARDs) is associated with a
reduced risk of CV events, most likely due to inhibitory effects on
inﬂammatory pathways [16,17].
Tofacitinib is an oral Janus kinase inhibitor for the treatment of
RA. Tofacitinib has demonstrated efﬁcacy and safety in patients
with RA at doses of 5 and 10 mg twice daily (BID) in Phase 2
[18–22] and Phase 3 randomized controlled trials (RCTs) of up to
24 months’ duration [23–28] and in long-term extension (LTE)
studies with up to 72 months of observation [29,30].
During the Phase 2 studies, increases in low-density lipoprotein
cholesterol (LDL-C) and high-density lipoprotein cholesterol
(HDL-C) levels were observed in patients with active RA receiving
treatment with tofacitinib [18,19,21,22,31]. Consequently, Phase 3
and LTE studies included adjudication of potential CV events and
deaths.
The purpose of the current analysis was to evaluate the CV
event rates and changes in blood pressure (BP) and lipid levels
from pooled Phase 3 and open-label LTE studies of tofacitinib in
patients with moderate to severe active RA.Methods
Study design and treatment
The six double-blind, Phase 3 RCTs included in this analysis
were of 6–24 months’ duration, and pooled in a single data set
(Table 1). Pooling was justiﬁed by the similarity of demographic
and baseline disease characteristics of patients across the studies.
The two open-label LTE studies (A3921024 [NCT00413699] and
A3921041 [NCT00661661]) [29] (Table 1) enrolled eligible patients
from two Phase 1, nine Phase 2, and six Phase 3 index studies of
tofacitinib. Details on individual study designs have been pub-
lished previously [23–28] and are summarized in Table 1. In all
studies, patients were permitted to receive treatment with non-
steroidal anti-inﬂammatory drugs (NSAIDs) and oral glucocorti-
coids, that is, r10 mg/day prednisone or equivalent, consistent
with rheumatology practice worldwide. Dosing of tofacitinib and
background DMARD therapy was required to be stable in Phase 1,
Phase 2, and 3 studies. In the LTE studies, dose adjustments of
tofacitinib and background DMARD therapy were permitted based
on the investigator’s assessment of efﬁcacy and safety. For the
purpose of the current analysis, the average total daily dose (TDD)
during the LTE studies was calculated by adding all doses received
by each patient and dividing by the number of days a dose wasreceived. TDDs of o15 mg/day and Z15 mg/day were categorized
as 5 and 10 mg BID groups, respectively.
All studies were conducted in accordance with the Declaration
of Helsinki and the International Conference on Harmonisation
Good Clinical Practice Guidelines. All patients provided written,
informed consent. The ﬁnal protocols, amendments, and informed
consent documentation were reviewed and approved by the
Institutional Review Board and/or Independent Ethics Committee
of each investigational site.
Patients
In Phase 3 studies, eligible patients aged Z18 years with active
moderate to severe RA were enrolled globally from North America,
Europe, Latin America, Asia, and Australia. Patients eligible for
enrollment in the LTE studies were aged Z18 years (A3921024) or
Z20 years (A3921041). Key inclusion criteria are detailed in
Table 1. Key exclusion criteria included: current or recent history
of severe, progressive, or uncontrolled renal, hepatic, hematolog-
ical, gastrointestinal, endocrine, metabolic, pulmonary, cardiac, or
neurological disease; or a 12-lead electrocardiogram at screening
that demonstrated clinically relevant abnormalities that might
have affected patient safety or interpretation of the study results.
The screening visit included an evaluation of vital signs, including
blood pressure and heart rate, and fasting lipid proﬁles.
Cardiovascular events
Adjudicated major adverse CV events (MACE) and congestive
heart failure (CHF) events were categorized and incidence rates
calculated. The endpoint of MACE was deﬁned as the composite of
the following events: CV mortality (including coronary, cerebro-
vascular, cardiac, and non-cardiac vascular events), and non-fatal
CV events (including MI and cerebrovascular events).
Measurement of lipid levels
Total cholesterol (TC), HDL-C, and triglyceride levels (fasting)
were assayed using conventional analytical techniques in all
studies. LDL-C levels were calculated using the Friedewald formula
[32]. When triglyceride levels were Z400 mg/dL, LDL-C was
measured directly by ultracentrifugation. Plasma concentrations
of apolipoprotein (Apo) A-1 and Apo B-100 were measured using
immunophelometry.
Blood pressure and hypertension
For all studies, BP measurements were obtained at the screen-
ing, all study visits, and at follow-up, and were recorded to the
nearest mmHg in the dominant arm after the patient had rested
for Z5 minutes. For recorded BP measurements, hypertension was
deﬁned using criteria speciﬁed in the Seventh Report of the Joint
National Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure (JNC7) [33]. By contrast, adverse
events (AEs) related to hypertension were identiﬁed and reported
by the investigators, then coded to preferred terms using MedDRA.
Statistical analyses
Data are reported through Month 24 for Phase 3 studies and
through 60 months of observation for LTE studies. All data
captured up to and including 10 April 2013 are included in this
analysis. For Phase 3 studies, data are presented by Months 0–3
(placebo comparison phase), Months 3–6 (placebo advancement
phase), and 46 months (tofacitinib-only phase). Data collection
and analyses for LTE studies were still ongoing at the time of the
Table 1
Summary of the tofacitinib clinical studies included in this analysis: A3921024, A3921032, A3921041, A3921044 (2-year data), A3921045, A3921046, A3921064, and
A3921069 (1-year data)
Study
Main inclusion
criteria Study duration
Study
treatments
Background
therapy
Number of
patients
randomized
Phase 3 studies
ORAL Start [26] Active RAa 24 months Tofacitinib 5 mg BID None – monotherapy 958
A3921069 MTX naïve Tofacitinib 10 mg BID
NCT01039688 MTXb
ORAL Sync [25] Active RAc 12 months Tofacitinib 5 mg BID Combination with csDMARDs 795
A3921046 DMARD-IR Tofacitinib 10 mg BID
NCT00856544 Placebod
ORAL Standard [28] Active RAa 12 months Tofacitinib 5 mg BID Combination with MTX 717
A3921064 MTX-IRa Tofacitinib 10 mg BID
NCT00853385 Placebod
Adalimumab 40 mg sc q2w
ORAL Scan [27] Active RAa 24 months Tofacitinib 5 mg BID Combination with MTX 797
A3921044 Z3 distinct joint erosions Tofacitinib 10 mg BID
NCT00847613 MTX-IR Placebod
ORAL Step [23] Active RAa 6 months Tofacitinib 5 mg BID Combination with MTX 399
A3921032 TNFi-IR Tofacitinib 10 mg BID
NCT00960440 Placebod
ORAL Solo [24] Active RAa 6 months Tofacitinib 5 mg BID None – monotherapy 611
A3921045 DMARD-IR Tofacitinib 10 mg BID
NCT00814307 Placebod
Long-term extension studies
ORAL Sequel [29] Patients from ﬁve Phase 2 studies, or from
China and Japan, initiated treatment with
tofacitinib 5 mg BID
A3921024
NCT00413699 Active RAe; participation in
a qualifying Phase 1,
Phase 2, or Phase 3 study
Long term Background csDMARDs or
monotherapy based on the
requirements of the index
studyA3921041 [29] Patients from the Phase 1 studies, the
remaining Phase 2 studies, and Phase
3 studies initiated treatment with
tofacitinib 10 mg BID, regardless of
treatment assignment in the index study
4827
NCT00661661
ACR, American College of Rheumatology; BID, twice daily; CRP, C-reactive protein; csDMARD, conventional synthetic disease-modifying antirheumatic drug;
DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; IR, inadequate response; MTX, methotrexate; q2w, once every 2 weeks;
RA, rheumatoid arthritis; sc, subcutaneously; TNFi-IR, inadequate response to tumor necrosis factor inhibitors.
a Diagnosis of RA based on the ACR 1987 revised criteria [59] and Z6 tender/painful joints (68-joint count) and Z6 swollen joints (66-joint count); ESR 428 mm/h
(in local laboratory); or CRP 4 7 mg/L.
b Starting dose of 10 mg per week that was incrementally increased to 20 mg per week by Week 8.
c Diagnosis of RA based on the ACR 1987 revised criteria [59] and Z4 tender/painful joints (68-joint count) and Z4 swollen joints (66-joint count); ESR 4 28 mm/h
(in local laboratory); or CRP 4 7 mg/L.
d Patients randomized to placebo were advanced in a blinded manner to tofacitinib 5 or 10 mg BID at 3 or 6 months.
e Diagnosis of RA based on the ACR 1987 revised criteria [59].
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may change for the ﬁnal, locked study database).
All safety analyses were descriptive in nature. Incidence rates
(unique patients with events per 100 patient-years of observation)
for adjudicated CV events were compared between treatment
groups and were based on the number of patients with an event
and the total exposure time censored at time of event, death, or
discontinuation from the study. The 95% conﬁdence intervals (CIs)Table 2
Summary of patients from the Phase 3 and LTE studies included in this analysis
0–6 Months 6–12 Months 12–18 Months 18–
Total patients, n 4069 3585 3154 244
Total pt-yrs of drug exposure 1893.30 1679.63 1367.34 112
LTE, long-term extension; N, number of patients; pt-yrs, patient-years.for incidence rates were based on maximum likelihood estimation
(Table 2).
In Phase 3 studies, adjudication of CV events was performed by a
blinded CV Safety Endpoint Adjudication Committee (CVSEAC)
comprised of three cardiologists independent of Pﬁzer. The adjudi-
cation process was implemented on 25 February 2009 after the
completion of Phase 2 studies and before the start of Phase 3 studies
but when the LTE studies were already ongoing. Therefore,24 Months 24–30 Months 30–36 Months 36–42 Months 442 Months
2 2151 1783 1344 370
8.75 966.32 772.85 406.01 34.52
Table 3
Baseline demographics in Phase 3 and LTE studies
Phase 3 studies LTE studies
Tofacitinib Tofacitinib Placebo - tofacitinib Placebo - tofacitinib Adalimumab Tofacitinib Tofacitinib All doses
5 mg BID 10 mg BID 5 mg BID 10 mg BID 40 mg sc q2w Methotrexate 5 mg BID 10 mg BID (5 and 10 mg BID)
(N ¼ 1589) (N ¼ 1611) (N ¼ 343) (N ¼ 338) (N ¼ 204) (N ¼ 186) (N ¼ 1452) (N ¼ 3374) (N ¼ 4826)a
Age (years)
Mean (range) 52.5 (1886) 51.7 (1885) 52.8 (1882) 52.2 (1880) 52.5 (2377) 48.8 (2080) 53.1 (1882) 53.0 (1886) 53.1 (1886)
Z65 years (%) 14.3 14.3 16.3 13.3 14.7 10.8 17.1 15.4 15.9
Gender (%)
Male: female 17.4: 82.6 15.8: 84.2 19.0: 81.0 18.6: 81.4 20.6: 79.4 22.0: 78.0 16.8: 83.2 18.1: 81.9 17.7: 82.3
Race (%)
White 61.4 62.5 66.8 62.1 72.5 68.3 46.6 70.5 3.2 16.3 10.0 63.3
Black 3.7 2.9 2.3 4.7 1.5 2.2 1.7 3.2 2.7
Asian 24.9 23.4 23.6 25.1 14.2 17.7 43.1 16.3 24.4
Other 10.1 11.2 7.3 8.0 11.8 11.8 8.7 10.0 9.6
Smoker (%)
Never: current: ex-smoker 66.6: 14.7: 18.7 68.1: 17.5: 14.4 59.2: 21.1: 19.6 66.4: 17.0: 16.7 65.5: 18.5: 16.0 67.2: 21.0: 11.8 73.6: 13.3: 13.1 65.7: 18.1: 16.2 67.9: 16.8: 15.3
Mean (SD) body mass index (kg/m2) 26.9 (6.5) 27.0 (6.3) 26.8 (6.6) 27.6 (7.1) 27.1 (5.5) 26.7 (6.1) 25.5 (5.8) 27.5 (6.5) 26.9 (6.4)
Tofacitinib Tofacitinib Adalimumab Tofacitinib Tofacitinib All doses
5 mg BID 10 mg BID All tofacitinib doses Placebo 40 mg sc q2w Methotrexate 5 mg BID 10 mg BID (5 and 10 mg BID)
(N ¼ 1589) (N ¼ 1611) (N ¼ 3200) (N ¼ 681) (N ¼ 204) (N ¼ 186) (N ¼ 1452) (N ¼ 3374) (N ¼ 4827)
Hypertension, n (%) 369 (23.2) 358 (22.2) 727 (22.7) 145 (21.3) 49 (24.0) 33 (17.7) 365 (25.5) 735 (22.1) 1100 (23.1)
Diabetes, n (%) 130 (8.2) 127 (7.9) 257 (8.0) 48 (7.0) 16 (7.8) 8 (4.3) 107 (7.4) 243 (7.2) 350 (7.3)
Mean (SD) 114.8 113.3 114.1 115.8 117.0 111.5 111.5 114.2 113.4
LDL-C (mg/dL) (34.2) (34.9) (34.5) (35.0) (34.3) (32.0) (32.6) (34.4) (33.9)
Mean (SD) 59.4 59.7 59.6 59.8 58.6 55.7 58.7 59.0 58.9
HDL-C (mg/dL) (16.9) (17.0) (16.9) (17.1) (16.5) (15.0) (16.3) (16.5) (16.5)
Mean (SD) 199.1 198.6 198.8 200.6 200.8 190.1 192.1 198.8 196.6
TC (mg/dL) (42.4) (42.8) (42.6) (41.7) (40.3) (39.7) (39.6) (41.7) (41.2)
Mean (SD) 124.6 128.6 126.6 125.2 126.1 115.2 113.3 125.5 121.8
Triglycerides (mg/dL) (68.7) (78.8) (74.0) (64.3) (60.2) (51.2) (63.1) (70.2) (63.4)
In Phase 3 studies, patients randomized to placebo were advanced in a blinded manner to tofacitinib 5 or 10 mg BID at Months 3 or 6.
The average total daily dose (TDD) during the LTE studies was calculated by adding all doses received by each patient and dividing by the number of days a dose was received. TDDs of o15 mg/day and Z15 mg/day were
categorized as 5 and 10 mg BID groups, respectively.
BID, twice daily; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LTE, long-term extension; q2w, once every 2 weeks; sc, subcutaneously; SD, standard deviation; TC, total cholesterol.
a One subject had no demographic data at the time of the analysis.
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Phase 3 program but only those that occurred after 25 February 2009
in the LTE studies. Exposures were calculated from either the date of
randomization in Phase 3 studies or 25 February 2009 in LTE studies
until the date of the event or the date of data cutoff. The use of the
implementation date in the adjudication process rather than the date
of randomization for determining tofacitinib exposure in the LTE
studies may underestimate exposures and overestimate the actual
incidence rates. This approach was selected to generate the most
conservative estimates of incidence rates.
Results
Patients
In total, 4271 patients (including those receiving adalimumab,
MTX, and placebo) from Phase 3 studies and 4827 patients enrolled
from Phase 1, Phase 2, or Phase 3 studies into the LTE studies were
included in the analyses, representing 3942 and 8699 patient-years
of exposure to tofacitinib, respectively. Patient baseline demographics
and clinical and laboratory data are presented in Table 3. Baseline
hypertension by JNC7 criteria was present in up to approximately
one-quarter of patients in both Phase 3 and LTE studies.
Major adverse cardiovascular events
In the Phase 3 studies, 23 events of MACE occurred in tofacitinib-
treated patients. Incidence rates for MACE were similar for tofaciti-
nib, placebo, and adalimumab, although considerably fewer patients
were observed on adalimumab overall and the total exposure to
adalimumab and number of MACE events in these patients was less
than in the other treatment groups. No events were observed in the
MTX treatment group (Table 4, Fig. 1A). The incidence rates for CV
mortality events and MI were low and similar for tofacitinib (both
doses) and adalimumab and no events were observed in the placebo
and MTX treatment groups (Table 4; Fig. 1B and C). Incidence rates
for non-fatal cerebrovascular accidents were low and similar for
tofacitinib (both doses) and placebo; no events were observed in the
adalimumab or MTX treatment groups (Table 4; Fig. 1D). The
incidence rates for CHF events were low and similar with both doses
of tofacitinib; there were no CHF events in the placebo, adalimumab,
or MTX treatment groups (Fig. 1E). Incidence rates for adjudicated CV
events were generally lower in the LTE versus Phase 3 studies
(Table 4, Fig. 1A–E). Three CV deaths were reported in the LTE studies
(tofacitinib 5 mg BID) (Table 4; Fig. 1B).
Lipid levels
Phase 3 studies
Mean LDL-C, HDL-C, TC, and triglyceride levels were similar across
all treatment groups at baseline (Table 3). Mean Apo A-1 ranged from
143.7 mg/dL to 154.9 mg/dL across all treatment groups and mean
Apo B-100 ranged from 93.6 mg/dL to 95.3 mg/dL. Mean percentage
changes from baseline for LDL-C, HDL-C, TC, and triglycerides were
greater for tofacitinib compared with placebo through Months 1–6,
adalimumab through Months 1–12 (with the exception of triglycer-
ides at Month 1), and MTX through Months 1–18 (with the exception
of LDL-C at Month 1 and HDL-C at Month 15) (Fig. 2A). In patients
treated with tofacitinib 5 and 10 mg BID, mean percentage changes
from baseline in Apo A-1 were quantitatively similar to mean
percentage changes from baseline in HDL-C values, with changes in
Apo B-100 similar to LDL-C, but 7–9% lower in magnitude. Mean
baseline LDL-C/HDL-C ratios were similar across all treatment groups.
Small mean changes in LDL-C/HDL-C ratio occurred for tofacitinib
5 and 10 mg BID and MTX through Month 24, placebo through
Month 6, and adalimumab through Month 12 (Fig. 2A).
Fig. 1. Incidence rates for CV events in the Phase 3 and LTE studies.
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In the LTE studies, mean baseline LDL-C, HDL-C, TC, and
triglyceride levels were consistent with those seen in the Phase 3
studies (Table 3). Mean Apo A-1 values were 148.9 mg/dL fortofacitinib 5 mg BID and 153.1 mg/dL for tofacitinib 10 mg BID.
Mean Apo B-100 values were 88.3 mg/dL and 94.4 mg/dL, respec-
tively, for tofacitinib 5 and 10 mg BID. LDL-C, HDL-C, TC,
and triglyceride levels in the tofacitinib 5 mg BID group did not
Fig. 2. Mean change from baseline in LDL-C, HDL-C, TC, triglycerides, and LDL-C/HDL-C ratio in the Phase 3 (A) and LTE studies (B).
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pattern was observed in the tofacitinib 10 mg BID group (Fig. 2B).
Mean percentage change from baseline in Apo A-1 and Apo B-100
was highly variable for both doses of tofacitinib throughout the LTE
studies, with small patient numbers at Months 1, 2, 45, 48, 51, 54,
57, and 60. The LDL-C/HDL-C ratio remained largely unchanged for
tofacitinib 5 and 10 mg BID over time (Fig. 2B).Blood pressure and hypertension
Phase 3 studies
Mean baseline systolic BP (SBP) and mean diastolic BP (DBP)
were similar across all treatment groups. SBP changes were small:
the mean SBP ranged from 125.6 at baseline to 125.2 at Month 3
for all tofacitinib doses (5 and 10 mg BID) and from 125.5 to 125.6
C. Charles-Schoeman et al. / Seminars in Arthritis and Rheumatism 46 (2016) 261–271268for placebo. Mean DBP ranged from 78.0 to 78.2 for all tofacitinib
doses during the ﬁrst 3 months and from 78.1 to 77.3 for placebo.
Both SBP and DBP remained stable up to 24 months across all
treatment groups.LTE studies
Baseline measurements for SBP and DBP for patients enrolled in
the LTE studies were consistent with the Phase 3 pooled data. SBP
remained stable over time and ranged from 125.2 at baseline to
124.2 at Month 60 for all tofacitinib doses (5 and 10 mg BID). Mean
DBP ranged from 77.8 at baseline to 77.6 at Month 60 for allTable 5
Hypertension-related adverse events in Phase 3 studies (A) and LTE studies (B)
(A)
Tofacitinib Tofacitinib
5 mg BID 10 mg BID
N ¼ 1589 N ¼ 1611
Up to Month 3, n (%)
Blood pressure diastolic increased 0 1 (0.1)
Blood pressure increased 7 (0.4) 6 (0.4)
Blood pressure systolic increased 0 1 (0.1)
Hypertension 27 (1.7) 43 (2.7)
Hypertensive crisis 1 (0.1) 3 (0.2)
Total 35 (2.2) 54 (3.4)
N ¼ 1824 N ¼ 1836
Months 36, n (%)
Retinopathy hypertensive 1 (0.1) 0
Blood pressure diastolic increased 0 0
Blood pressure increased 2 (0.1) 3 (0.2)
Blood pressure systolic increased 0 1 (0.1)
Hypertension 22 (1.2) 22 (1.2)
Hypertensive crisis 1 (0.1) 0
Total 26 (1.4) 26 (1.4)
N ¼ 1429 N ¼ 1443
46 Months, n (%)
Hypertensive cardiomyopathy 0 1 (0.1)
Blood pressure increased 6 (0.4) 4 (0.3)
Blood pressure systolic increased 1 (0.1) 0
Essential hypertension 0 0
Hypertension 38 (2.7) 29 (2.0)
Hypertensive crisis 1 (0.1) 1 (0.1)
Total 45 (3.1) 34 (2.1)
(B)
Tofacitinib
5 mg BID
n (%) N ¼ 1452
Retinopathy hypertensive 0
Blood pressure abnormal 0
Blood pressure diastolic increased 0
Blood pressure increased 22 (1.5)
Metabolic syndrome 0
Hypertensive encephalopathy 1 (0.1)
Accelerated hypertension 1 (0.1)
Blood pressure inadequately controlled 0
Essential hypertension 0
Hypertension 140 (9.6)
Hypertensive crisis 5 (0.3)
Systolic hypertension 0
Total 169 (11.6)
In Phase 3 studies, patients randomized to placebo were advanced in a blinded manne
includes placebo patients who advanced to tofacitinib where applicable.
The average total daily dose (TDD) during the LTE studies was calculated by adding all dos
TDDs of o15 mg/day and Z15 mg/day were categorized as 5 and 10 mg BID groups, re
BID, twice daily; LTE, long-term extension; q2w, once every 2 weeks; sc, subcutaneousltofacitinib doses. SBP and DBP remained stable over time in both
tofacitinib treatment groups.
Hypertension
Across Phase 3 and LTE studies, approximately the same
percentage (17–25%) of patients in the tofacitinib, adalimumab,
MTX, and placebo treatment groups who were hypertensive at
baseline according to JNC7 criteria continued to meet the criteria
for hypertension at each visit (Supplementary Table 1). There were
few reports of hypertension-related AEs in the Phase 3 and LTE
studies (Table 5). In the Phase 3 studies, the number of
investigator-reported AEs of hypertension was slightly higher inAll tofacitinib Adalimumab
doses
N ¼ 3200
Placebo 40 mg sc q2w Methotrexate
N ¼ 681 N ¼ 204 N ¼ 186
1 (0.03) 0 0 0
13 (0.4) 3 (0.4) 0 0
1 (0.03) 0 0 0
70 (2.2) 7 (1.0) 0 2 (1.1)
4 (0.1) 0 0 0
89 (2.8) 10 (1.5) 0 2 (1.1)
N ¼ 3660 N ¼ 221 N ¼ 204 N ¼ 186
1 (0.03) 0 0 0
0 1 (0.5) 0 0
5 (0.1) 0 0 0
1 (0.03) 0 0 0
44 (1.2) 1 (0.5) 0 0
1 (0.03) 0 0 0
52 (1.4) 2 (0.9) 0 0
N ¼ 2872 – N ¼ 204 N ¼ 186
1 (0.03) – 0 0
10 (0.3) – 0 1 (0.5)
1 (0.03) – 0 0
0 – 1 (0.5) 0
67 (2.3) – 2 (1.0) 1 (0.5)
2 (0.1) – 0 0
79 (2.8) – 3 (1.5) 2 (1.1)
Tofacitinib All doses
10 mg BID (5 and 10 mg BID)
N ¼ 3375 N ¼ 4827
1 (0.03) 1 (0.02)
1 (0.03) 1 (0.02)
3 (0.1) 3 (0.1)
34 (1.0) 56 (1.2)
2 (0.1) 2 (0.04)
0 1 (0.02)
1 (0.03) 2 (0.04)
1 (0.03) 1 (0.02)
1 (0.03) 1 (0.02)
168 (5.0) 308 (6.4)
10 (0.3) 15 (0.3)
2 (0.1) 2 (0.04)
224 (6.6) 393 (8.1)
r to tofacitinib 5 or 10 mg BID at Months 3 or 6. The “All tofacitinib doses” group
es received by each patient and dividing by the number of days a dose was received.
spectively.
y.
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Month 6.
Across Phase 3 and LTE studies, most hypertension-related AEs
were graded as mild to moderate in severity by the investigators.
Serious adverse events (SAEs) related to hypertension occurred in
one patient in the Phase 3 studies [hypertension (n ¼ 1)] and
resulted in discontinuation from the study. In addition, four
patients discontinued from the Phase 3 studies due to
hypertension-related AEs [BP increased (n ¼ 2), hypertension
(n ¼ 1), and hypertensive crisis (n ¼ 1)]. In the LTE studies, 15
patients reported SAEs of hypertension [hypertension (n ¼ 8],
accelerated hypertension (n ¼ 1), and hypertensive crisis (n ¼ 6)]
resulting in ﬁve discontinuations from the study [hypertensive
crisis (n ¼ 4); hypertension (n ¼ 1)].Discussion
In the current pooled analyses, which included 3942 patient-
years of follow-up in the Phase 3 studies and 8699 patient-years of
follow-up in the LTE studies, treatment with tofacitinib 5 or
10 mg BID was associated with a low CV event rate, despite short-
and long-term increases in traditional cholesterol levels. Rates of
CV events (range of incidence rates per 100 patient-years) for
tofacitinib-treated patients, including MI events (0.12–0.17),
CHF (0.06–0.33), and cerebrovascular events (0.28–0.29), did
not increase with longer treatment duration. These rates were
generally similar to rates reported in past RA studies, including
studies of RA patients treated with TNFi [1,2,5,6,34–36]. In an
observational study of 236 patients with RA, an IR of 3.43/100
patient-years was reported for CV events (CV-related hospital-
izations, including MI, stroke or other arterial occlusive events, or
arterial revascularization procedures) [6]. In a cohort study of
25,385 residents of British Colombia with RA, IRs of 5.3/1000
patient-years and 14.8/1000 patient-years were reported, respec-
tively, for MI and for all CV events (CV-related hospitalizations,
including MI, stroke, or death from CVD) [2]. In another study of
983 patients with RA recruited from a regional register, IRs of 14.0/
1000 patient-years and 35.4/1000 patient-years were reported for
the ﬁrst CVD event in patients treated with TNFi (etanercept or
inﬂiximab) and for those without prior TNFi treatment, respec-
tively [35]. In the LTE study of tofacitinib, more than 500 patients
were treated with tofacitinib for 43.5 years; and 57 patients were
treated for 5 years.
The incidence rates for MACE events in all treatment groups
(0.34–1.68) correspond to a 10-year Framingham CV risk of 610%,
which is categorized as low in the general population [37]. Although
the incidence rates for CV events were generally similar between
treatment groups, the conﬁdence intervals were wide due to the
small number of events; therefore, differences between tofacitinib,
placebo, adalimumab, and MTX cannot be excluded with certainty.
When ﬁndings were compared between the Phase 3 and the LTE
studies there was no increase in the incidence rate of CV events as a
function of treatment duration.
Overall, the results of this study are generally consistent with
those observed in other studies of DMARD therapy for RA [38,39].
Systematic literature reviews and meta-analyses of the relation-
ship between MTX and CVD occurrence reported that MTX treat-
ment is associated with a low risk of CVD (21% lower in patients
with MTX than in those without) [38] and MI [39]. Recent data
indicate that use of TNFi in patients with RA is associated with a
decreased risk of CV events [16,17,40,41] and that the risk
decreases further with long-term use [41]. In particular, a retro-
spective cohort study of 2101 patients with RA reported a lower
risk of coronary artery disease in patients treated with TNFi versus
those with no prior TNFi treatment [41]. Another retrospectivecohort study using data from the MarketScan claims database
reported that following index prescription, each additional
6 months of TNFi therapy use versus non-use reduced the risk of
any CV event by 12% [42]. By contrast, NSAIDs and glucocorticoids
are generally considered to impact coronary heart disease risk
negatively in patients with RA [43].
Increases in serum LDL-C, HDL-C, and TC were observed within
1–3 months of tofacitinib treatment, were greater compared with
placebo, adalimumab and MTX, and stabilized after Month 3; there
was little change in LDL-C/HDL-C ratios. Corresponding increases
in Apo A-1 and Apo B-100 levels were also noted with tofacitinib.
While further studies are in progress, the analysis of the data
presented in the current work does not suggest an increase in CV
events associated with these lipid changes.
Similar cholesterol increases noted with tofacitinib have also
been reported for other DMARD therapies, including tocilizumab
[44], and have included simultaneous increases in LDL-C, HDL-C,
and TC combined with little or no change in the LDL-C/HDL-C ratio
[44–49]. The degree of cholesterol elevations with other DMARD
therapies has varied considerably depending on the patient
population, treatment response, and trial/study design.
Mean BP levels remained stable over time and there were no
changes in the proportion of patients with hypertension as per
JNC7 criteria. There were few reports of hypertension-related AEs
during the Phase 3 and LTE studies. In the Phase 3 studies, the
number of investigator-reported AEs of hypertension was slightly
higher in the tofacitinib 5 and 10 mg BID groups compared with
the placebo group through Month 6. No AEs related to hyper-
tension were reported in patients treated with adalimumab up to
Month 6 but did occur in patients treated with MTX during
Months 1–3 and beyond Month 6. Few patients discontinued the
studies due to hypertension-related AEs.
For all patients with RA, annual CV risk assessment using
national guidelines is recommended [50]; however, current
assessment tools and guidelines may underestimate the overall
CV risk [51,52]. In this regard, a high frequency of carotid plaques
were observed in patients with RA included in the category of
moderate CV risk according to the modiﬁed EULAR systematic
coronary risk evaluation (SCORE) [53]. Previous work has eval-
uated the effects of tofacitinib on the structural and functional
characteristics of lipoproteins in addition to its effects on choles-
terol levels [54,55]. These data support a growing body of work
[56–58] that suggests the importance of the functional and
structural characteristics of lipoproteins as well as levels of
cholesterol in the assessment of CV risk.
In summary, the current work suggests a low incidence of CV
events and CHF in patients receiving tofacitinib in both
Phase 3 and LTE studies despite increases in cholesterol, including
LDL-C levels. The CV event rates with tofacitinib were generally
similar to those seen for placebo, adalimumab and MTX, and did
not increase over time. These data are consistent with previously
published CV event rates among patients with RA, including
those treated with TNF inhibitors. LTE studies are ongoing and
further analyses with longer observational periods are required
to conﬁrm these ﬁndings. A post-marketing surveillance study
(NCT02092467) comparing the safety of tofacitinib versus TNFi
with respect to MACE and malignancies is currently underway.Competing interests
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